Classification No.	I -Safety-1	Safety, Health and	Revision Date	Sep. 11,2023
Page	i	Environment Policy	Revision No.	0.1

Revision History

0.1	Revision(Comprehensive Environmental Policy Inclusion)	2023.09.11.
0	Enactment	2023.03.02.
Revison No.	Revision Page / Contents	Date

Classification No.	I -Safety-1	Safety, Health and	Revision Date	Sep. 11,2023
Page	1	Environment Policy	Revision No.	0.1

Table of Contents

No.	Category	Page
1.	The Purpose of Policy	. 1
2.	The Scope of Application	. 1
3.	The Organization of Propulsion	. 1
4.	Governance	. 1
5.	Strategy	. 2
6.	SHE Detailed Strategies	. 8
7	Risk Management	17

Classification No.	I -Safety-1	Safety, Health and	Revision Date	Sep. 11,2023
Page	1 / 17	Environment Policy	Revision No.	0.1

1. The Purpos of Policy

SK Biopharmaceuticals' s safety, health and environment policy aims to make our home society and environment sustainable. We consistently promote safety, health and environment policy to create a safe workplace and preserve the environment without compromising the value pursued by customers, business partners, stockholders, and various stakeholders in society.

2. The Scope of Application

This policy is applied to all employees, subsidiaries, and suppliers involved in SK Biopharmaceuticals's corporate activities.

3. The Organization of Propulsion

SK Biopharmaceuticals conducts final decisions by the ESG/Strategic Committee within the Board of Directors to strengthen the company—wide promotion of safety, health and environmental management. Overall issues affecting safety, health and environmental management are managed by Headquarter of Corporate Culture&HR, and major issues are reported to the Chief Executive Officer(CEO). The CEO makes decisions on key issues, and the key issues are reported to the top decision—making body, the Board of Directors and the ESG/Strategic Committee.

4. Governance

4.1 Board of Directors & Biz/ESG Committee

SK Biopharmaceuticals regularly reviews and approves environmental/safety management performance through the establishment, inspection, and evaluation of KPIs by establishing ESG/strategic committees for major decision—making and professional deliberation in SHE. It also operates environmental impact assessment procedures related to air and water pollutant emissions, waste, greenhouse gases, energy, and water for all board agendas. The CEO is responsible for environmental management, and the internal regulations, Environmental Manual, stipulate the authority to ensure the appropriateness of environmental policies and environmental objectives. In addition, the CEO's responsibility and authority is to approve management reviews that include achieving environmental goals, compliance

Classification No.	I -Safety-1	Safety, Health and	Revision Date	Sep. 11,2023
Page	2 / 17	Environment Policy	Revision No.	0.1

with laws and regulations, and continuous improvement tasks. To strengthen environmental management at all stages of research, ESG/Strategic Committee, a meeting of one executive director and one non-executive director, is held once a year to discuss risks and countermeasures, and important decisions are reported to the board and management.

Under the leadership of CEO and Chief Technology Officer (CTO), who was appointed as the Health and Safety Management Officer, the head office establishes and implements an environmental safety and health plan.


4.2 ESG Management Organization



^{*} It operates SHE organizations for each business site.

5. Strategy

5.1 Summary



Pollutant: Total annual emissions(kg) of sulfur oxides, nitrogen oxides, and volatile organic compounds among pollutants that need to be managed in accordance with the Air Environment Conservation Act.

Specific Water Hazardous Substances: Toluene, xylene, vinyl chloride, and trichloroethylene among substances used as SKBP raw materials
as hazardous substances designated under the Water Environment Conservation Act.

Classification No.	I -Safety-1	Safety, Health and	Revision Date	Sep. 11,2023
Page	3 / 17	Environment Policy	Revision No.	0.1

5.2 Environmental Management


SK Biopharmaceuticals will continue its efforts to become a big biotech that achieves climate change response and minimizing environmental impact in the management process. Increasing environmental resilience through various environmental programs and improvement activities is not just considering corporate social responsibility and investment response, but also a key strategy in SK Biopharmaceuticals's management process to reach 'Healthy Future for Everyone'.

1) Stronger Together

SK Biopharmaceuticals recognizes that environmental policies and strategies cannot be achieved alone, and will practice and participate in the core value of SHE management with all stakeholders such as workers/subsidiaries/investment companies/subcontractors/special types of workers.

The first effort is to submit environmental objectives for each organization from 2022 to strengthen environmental management leadership, which the company checks whether KPI is achieved and reflects in the performance evaluation of executives and organizations.

2) 2030 Environmental Management Major Challenges



Classification No.	I -Safety-1	Safety, Health and	Revision Date	Sep. 11,2023
Page	4 / 17	Environment Policy	Revision No.	0.1

5.3 Environmental Management Policy

SK biopharmaceuticals recognizes that safety, health, and environment are fundamental factors to secure competitiveness in differentiated research activities, and declares that it will faithfully implement the following to continuously improve safety, health, and environmental performance.

- We observe relevant laws and establish and operate environmental regulations that lead the domestic and foreign industries.
- 2. We continuously discover and improve harmful, dangerous, or unstable situations.
- 3. Based on social responsibility, we actively support and cooperate to improve the environment of all members, business partners, and communities.
- 4. We disclose information transparently, communicate faithfully with external and stakeholders, and obtain cooperation.
- 5. We contribute to ESG management by conducting continuous environmental improvement activities.
- 6. We pursue continuous innovation in the entire process of research activities for eco-friendly research results.
- 7. We create a pleasant research environment and establish an organizational culture that thoroughly complies with basic principles.

1) Policy Coverage

The SHE policy is applied to all workers, subsidiaries, investment companies, suppliers, contract workers, and special types of workers engaged in SK Biopharmaceuticals' corporate activities.


5.4 Environmental Management System (EMS)

SK Biopharmaceuticals aims to certify ISO 14001, an international standard for environmental management systems, for all sites conducting R&D. In 2022, the company completed the certification of its headquarters in Pangyo, Korea, and passed the Surveillance review in 2023. SK

Classification No.	I -Safety-1	Safety, Health and	Revision Date	Sep. 11,2023
Page	5 / 17	Environment Policy	Revision No.	0.1

Biopharmaceuticals plans to establish a consistent environmental management system for all businesses and subsidiaries by promoting ISO 14001 certification for subsidiaries around the world.

1) Operating System



5.5 International Certification

SK Biopharmaceuticals has acquired a safety and health management system (ISO 45001: 2018) and an environmental management system (ISO 14001: 2015) for its Korean headquarters with research facilities.

According to the international standard system, we continue to make efforts to improve the SHE management system by conducting periodic safety, health, and environmental regulations and compliance audits.

1) ISO 14001/45001 Certification

Certification Type	Scope	Acquisition Date	Examiner
ISO 45001 (Safety and Health management)	Headquarters: Development of New Drugs	May 11, 2023	LRQA

Classification No.	I -Safety-1	Safety, Health and	Revision Date	Sep. 11,2023
Page	6 / 17	Environment Policy	Revision No.	0.1

ISO 14001 (Environmental management)	(Completed 100%: 1 out of 1 site)	May 23, 2022	Korean Foundation for Quality(KFQ)
--	-----------------------------------	--------------	---------------------------------------

2) Certificate



5.6 Environmental Accident Response

SK Biopharmaceuticals has established an environmental accident response system based on international standards and conducts emergency response training. In each site, we have established a scenario response system in accordance with guidelines to respond to and report environmental accidents if they occur. Furthermore, we have formulated accident management guidelines to strengthen the reporting system for environmental accidents and are making every effort to prevent human and material damages.

1) The number of environmental accidents reported

Category	2020	2021	2022	2023 Goal
Air/Water Quality, Waste, Chemical Substances	-	-	-	-

2) Environmental-related Education

SK Biopharmaceuticals has expanded its education programs not only

Classifica No.		I -Safety-1	Safety, Health and	Revision Date	Sep. 11,2023
Page	е	7 / 17	Environment Policy	Revision No.	0.1

for legal compliance but also for capacity building to enhance environmental awareness. This is to ensure the systematic operation of the environmental management system. We manage educational outcomes and have increased the scope of our education programs.

		Performance		
Category	Training Title	Personnel	Education Time (hour)	
Legal Education	Air/Water Quality Sector Manager Training	2	32	
Capacity Building Education	ISO Internal Auditor Traning	4	32	

5.7 SHE Compliance

SK Biopharmaceuticals is committed to complying with various environmental regulations and standards at the local, national, and international levels. These compliance efforts are crucial in establishing a direction for adopting more efficient and resource—saving practices in our business activities. As a result, environmental compliance can lead to cost savings, a reduction in environmental pollutants such as waste, and optimization of energy and water usage.

We have established a compliance obligation management procedure to promptly identify and proactively address evolving environmental regulations and other requirements. This process minimizes the impact on business activities. We conduct annual periodic environmental compliance assessments, which include evaluation criteria for various aspects such as general environmental compliance, air quality, water quality, waste management, chemical substances, and more. Additionally, we actively incorporate external opinions through regular monthly consultations related to environmental regulations.

1) Compliance Audit Status for SHE Management

Classification	Audit Cycle	Audit Leading Department
Initial Stage Phase 1 / 2	Initial One-time	External Audit Agency (LRQA, KFQ)
Internal Audit	Once a year	SHE Team
Surveillance	Once a year	External Audit Agency (LRQA, KFQ)

Classification No.	I -Safety-1	Safety, Health and	Revision Date	Sep. 11,2023
Page	8 / 17	Environment Policy	Revision No.	0.1

Re-Certification	Once every 3 years	External Audit Agency (LRQA, KFQ)
------------------	--------------------	-----------------------------------

6. SHE Detailed Strategies

6.1 Management of Wastes

1) Commitments

SK Biopharmaceuticals deals with a variety of chemical substances and also disposes of materials with biological hazards as a part of its business operations. We are deeply concerned about the social and ecological impact of such waste materials, and as a result, we have established systematic waste management procedures and disposal guidelines that cover the entire process from acquisition to disposal.

We are committed to continuously improving its waste management policies to prioritize environmental sustainability in its business activities. This includes efforts to reduce waste generation and landfill disposal while increasing resource and energy circulation rates.

2) Action Plan / Achievement / Goal

Action Plan	Achievement ('22)	Goal('30)
· Establishing a Resource Circulation System Based on the 3R(Reduce-Reuse-Recycle) Principles	 Discovering Recyclabel Items (e.g., Used Solvents) 	· Achieving an 85% Waste Recycling Rate ·
Expanding the Waste-to-Energy Ratio (Steam, Electricity) Through the Value Chain	• Incineration of All Hazardous Waste (100%)	 Reducing Incinerated Waste Discharge by 8 tons
· Biological Activity Removal of LMO Waste	· Zero Findings in On- Site Inspection by Regulatory Authorities	 Maintaining Zero Findings in On-Site Inspections by Regulatory Authorities
· Increasing Recycling through Phase Separation, Reducing Hazardous Waste Generation	· Reducing the Discharge of Used Solvents by 1%	· Achieving Moisture Content in Used Solvents of Less Than 30%
· Enhancing the Evaluation of Waste Management Service Providers	 Conducting Evaluations for Over Half of the Waste Disposal Contractors 	 Conducting Evaluations for All of the Waste Disposal Contractors

3) All Hazardous Wastes Management Roadmap

Classification No.	I -Safety-1	Safety, Health and	Revision Date	Sep. 11,2023
Page	9 / 17	Environment Policy	Revision No.	0.1

2024	2026	2028	2030
Classification and Systematization of Hazardous Waste Sorting and Management	2 Increasing Hazardous Waste Recycling	3 Enhancing Value Chain Collaboration	4 Expanding Resource Circulation of Hazardous Waste
Enhanced Segregated Disposal of Waste by Physical Characteristics Enhanced Education and On-Site Inspections Enhancement of Waste Classification	Achieving a 20% Recycling Rate According to ZWTL ²) Standards Reducing Incineration Treatment Rate by 10% Compared to 2022 Conducting Evaluations for All of the Waste Disposal Contractors	Achieving a 40% Recycling Rate According to ZWTL Standards Reducing Incineration Treatment Rate by 30% Compared to 2022 Collaborative Program Initiatives with Partner Companies	Achieving a 85% Recycling Rate According to ZWTL Standards Establishing a Resource Circulation IoT System Conducting a Life Cycle Assessment for Hazardous Waste

²⁾ ZWTL (Zero Waste To Landfill): It is used as an international indicator for waste recycling rates, and it is evaluated and certified by external certification agencies, receiving ratings

4) Waste Management Data

Category	2020 (Base line)	2021	2022	Change vs 2020(%)
Recycling Rate(%)	0	0	0	O
Incineration Treatment Rate (%)	100	100	100	0

5) Hazardous Waste Treatment Site Assessment

Category	2020 (Base line)	2021	2022	Change vs 2020(%)
On-Site Assessment Rate (%)	50 (Half of the Contracted Companies)	50 (Half of the Contracted Companies)	50 (Half of the Contracted Companies)	0 %

6) Short-Term/Long-Term Reduction Goal Roadmap for Environmental Hazardous Substance

① Short-Term Reduction Goal(~2025)

Core Objective	Performance in 2022	Plans for 2023
A 1% annual reduction in hazardous substance emissions by 2025	In 2022, the generated waste amount was approximately 41.8 tons, achieving a reduction of around 10% compared to the target of 46.3 tons	Setting a target of 41.4 tons for waste generation in 2023, aiming for a reduction of approximately 1% compared to 2022

② Long-Term Reduction Goal(~2035): Reduction rate of hazardous substance emissions intensity compared to the previous year

Category	Unit	Reduction Target (~'26)	Reduction Target (~'28)	Reduction Target (~'30)
Air Pollutants	%	-44	-56	-66
Water Pollutants	%	-44	-53	-62

Classification No.	I -Safety-1	Safety, Health and Environment Policy			Revisio Date		Sep. 11,2023
Page	10 / 17				Revision	No.	0.1
	Waste Disposal Amount	% -41 -		-50		-58	

6.2 Management of Chemicals

1) Commitments

SK Biopharmaceuticals recognizes the need for minimizing the handling of hazardous chemicals in order to ensure a healthy future for employees, society, and the environment. We encourage employees to replace hazardous chemicals such as benzene with low—hazard substances whenever possible and implement hazard management strictly by referring to the Health Code of the National Fire Protection Association (NFPA). We also discharge wastewater separately to minimize the volume of hazardous chemicals, such as solvents, acids, and alkalis, in the discharged effluent, reducing our environmental impact. To ensure compliance, we provide guidance to all employees on procedures for the management of chemical substances and waste.

Action Plan	Achievement ('22)	Goal('30)
 Replace CMR* substances and others with less harmful substances 	· Complete Benzene Disposal/Substitution**	· Life-cycle Management of CMR Substances
· Managing Chemicals Based on Hazard Information	· Laboratory-Specific Hazard Information Update	 Maintaining zero cases of occupational disease
• Enhancing Training Procedures for Handlers of Hazardous Chemicals	Completion of 2 hours of chemical substance- related training per person	• Education time : Ensure a minimum of 6 hours per person

^{*} CMR(Carcinogenicity, Mutagenicity, Reproductive toxicity): Substances confirmed to be harmful to the human body due to their carcinogenic, mutagenic, and reproductive toxicity properties

^{**} Alternative substance : Benzene \rightarrow Replacing with a less hazardous material

Classification No.	I -Safety-1	Safety, Health and	Revision Date	Sep. 11,2023
Page	11 / 17	Environment Policy	Revision No.	0.1

3) Hazardous Chemicals Management Roadmap



4) Training for Chemical Substances—Handling Employees

SK Biopharmaceuticals conducts special safety and health training for researchers who handle chemical substances, and includes contents related to MSDS in the training programs. To strengthen understanding of regulations relating to chemical substances and ensure practical management of chemicals at the research site, we conduct special safety and health trainings for researchers under the supervision of the SHE specialists.

[First Half of 2023 Monthly Chemical Substance Training Topics]

Categroy	Торіс	Participating Department	Total Training Hours	Total No. of Participants
January	Preparation of exemption documents for the registration of imported/exported chemicals	All R&D Departments,	36	24
February	Preparation of daily log for special management substances and regulated substances	Tooma oto		35
May	Compliance with the Narcotics Control Act	All R&D	102	51
June	Compliance with Act on the De		100	50

6.3 Management of Air Pollutants

1) Commitments

SK Biopharmaceuticals strictly adheres to legal standards for the emissions of air pollutants such as particulate matter, sulfur compounds, nitrogen oxides, generated during research processes. They are continuously dedicated to various efforts, including technological

Classification No.	I -Safety-1	Safety, Health and	Revision Date	Sep. 11,2023
Page	12 / 17	Environment Policy	Revision No.	0.1

development and facility investments, to reduce emissions consistently.

2) Action Plan / Achievement / Goal

Action Plan	Achievement ('22)	Goal('30)
 Operation of Internal Emission Standards Exceeding Legal Requirements 	• 10% Strengthening of Internal Emission Standards	· Enhanced by 50% Compared to Legal Standards
• Zero Emissions of Hazardous Substances Directly Released into the Atmosphere	• Emission of Regulated Pollutants Less Than 650kg	· Zero Emission of Regulated Pollutants
• Transition to Renewable Energy Fuels (Electrification)	· Continuously Exploring New Technologies, Including Electrification	 Replacement with Electric Boiler/Generator
· Enhanced Air Pollutant Monitoring	• Measurement of Air Pollutants at Least Twice Annually	· Monthly Measurement of Air Pollutants (12 times per year)
 Enhancement of Operating Standards for Hazardous Chemical Capture Facilities 	· Optimization of Management Standards	· Introduction of an Efficiency Management System for Capture Facilities

3) Introduction of an Efficiency Management System for Capture Facilities

Measurement	Legal Standards		Internal	Compared to Legal	
Items	Measurement Cycle	Concentration	Measurement Cycle	Concentration	Standards (%)
Dust		30mg/Sm3		27mg/Sm3	-10%
Sox (Sulfur Oxides)	Once every 6 months	35ppm	Once every month	Oppm	-100%
NOx (Nitrogen Oxides)		40ppm		36ppm	-10%
THC (Total Hydro Carbon)	_	_		500ppm	_

4) Air Pollutant Reduction Status

Measurement Items	Concentration Before/After Facility Improvement (ug/m3)		Reduction Rate(%)	
	Before (2023.4)	After (2023.5)		
Dust	15.4	8.7	43.5(%)	
Sox (Sulfur Oxides)	9.5	7.5	21.1(%)	

Classification No.	I -Safety-1	Safety, Health and	Revision Date	Sep. 11,2023
Page	13 / 17	Environment Policy	Revision No.	0.1

NOx (Nitrogen Oxides)	0.019	0.017	10.5(%)
THC (Total Hydro Carbon)	461.8	132.1	71.4(%)

6.4 물 관리

1) Commitment

Our company falls into the "medium-high" category of the Water Stress Index, as publicly disclosed by the World Resources Institute (WRI). This indicates that water scarcity does not have a significant impact on our business activities. Additionally, since we do not directly own manufacturing facilities, we approach water resource management from a water quality management perspective. We contribute to water circulation by reducing the discharge of hazardous substances in our wastewater and strengthening our management beyond legal regulatory standards.

Action Plan	Achievement ('22)	Goal ('30)
· Contributing to Data Reliability Through Monthly Wastewater Quality Analysis	· Monthly Water Quality Analysis Conducted	· Monthly Water Quality Analysis and Operation of the Water Quality Tele Monitoring System(TMS)**
· Minimization of Specific Water Quality Hazardous Substance* Discharge	· Zero Emission of Hazardous Substances	 Maintaining Zero Discharge of Hazardous Substances
Water Conservation Campaign Implementation	· A 10% Reduction in Wastewater Discharge Compared to 2021	· Reduced Wastewater Discharge by 10% Compared to the Baseline Year (2020)
· Improvement in Water Recycling Rate	· Exploring Water Recycling Ideas	· Improved Water Reuse Rate by Over 8%

^{*} Toluene, Xylene, Vinyl Chloride, and Trichloroethylene are substances used within our company that fall under designated hazardous materials according to Water Environment Conservation Act.

^{**} Monitoring system for real-time water quality management

Classification No.	I -Safety-1	Safety, Health and	Revision Date	Sep. 11,2023
Page	14 / 17	Environment Policy	Revision No.	0.1

3) Wastewater Data

Categ	2020 (Base line)	2021	2022	Change vs 2020(%)	
Frequency of Water (cas	2	2	12*	500%	
Wastewater Dischar	Wastewater Discharge Volume (Ton)			1,324	-10%
	Vinyl Chloride	0	0	0	0%
Discharge Quantity of Water Quality	Toluene	0	0	0	0%
Pollutants (kg)	Xylene	0	0	0	0%
	Trichloroethylene	0	0	0	0%

^{*} Measurement of all substances regulated by the relevant laws (pH, COD, TOC, etc.)

6.5 Safety and Health Management

1) Commitments

SK Biopharmaceuticals recognizes that workplace safety and health issues are critical concerns that can directly result in human harm.

Under the leadership of the Safety and Health team, we hold industry safety and health committee meetings at least once every quarter to actively solicit and manage Employee's opinions on safety and health matters. Furthermore, we have established an employee and partner company occupational management system to achieve our three—year long—term goals for advancing safety and health management excellence, in alignment with enhancing safety and health management practices.

Action Plan	Achievement ('22)	Goal ('30)
Compliance with Safety and Health Regulations and Adherence to SHE Guidelines	· Establishment and Operation of Health Diagnosis Procedures	· Expansion of Safety and Health Prevention Program
· Creating a Safe and Pleasant Research Environment	· Conducting Workplace Environment Measurements Twice a Year	· Enhancement of Indoor Air Quality Measurement

Classification No.	I -Safety-1	Safety, Health and	Revision Date	Sep. 11,2023
Page	15 / 17	Environment Policy	Revision No.	0.1

· Identification	and	Mitigation	of	Hazardous	· Conducting Risk	· Establishment of a
Factors					Assessment Annually	Continuous Risk
						Assessment System

3) Establishment of a Continuous Risk Assessment System

Classification	Phase1 (2023)	Phase2 (2024)	Phase3 (2025)
Goals for Advancing Safety Management System	 Enhancement of Compliance System for the Act on Serious Accidents Punishment Establishment of a Supplier Registration Evaluation System 	 Enhancing the Participation Environment for Employee Safety and Health Establishment of Supplier Selection and Evaluation System 	 Ongoing Enhancement of Employee-Led Safety and Health Management Enhancement of SHE Management System for Partner Companies
Goals for Advancing Health Management System	Foundation Survey for Health Management System Implementation Establishment of a Program for Preventing Suffocation Hazards	Establishment of Health Management System Implementation Strategies Improvement of Suffocation Hazard Prevention Program	 Implementation of Health Management System Policy and Programs Evaluation of Suffocation Hazard Prevention Program

6.6 Management of Greenhouse Gas


1) Commitments

SK Biopharmaceuticals recognizes climate change adaptation as an essential element of its management strategy and has declared the goal of achieving net zero greenhouse gas emissions by 2040, aiming to reach a net emissions level of zero by 2040. This declaration is based on the '2040 Net Zero Roadmap,' which was formulated adopting the RCP-2.6 scenario used in the IPCC Fifth Assessment Report. The Roadmap has been supplemented with socio-economic elements using the SSP1-2.6 (Shared Socioeconomic Pathways) scenario, as featured in the IPCC Sixth Assessment Report published in May 2022. Through this, SK Biopharmaceuticals commits to actively participating in achieving low-emission scenarios, limiting global warming to 1.5 degrees Celsius, and planning and implementing practical mitigation measures.

Classification No.	I -Safety-1	Safety, Health and	Revision Date	Sep. 11,2023
Page	16 / 17	Environment Policy	Revision No.	0.1

Action Plan	Achievement ('22)	Goal ('30)
 Establishing a Net Zero Direction with a Focus on RE100 	· Enhancement of the Net Zero Roadmap	· Achieving Compliance with the 1.5℃ Scenario
• Enhancement of Scope 3 Emissions Measurement and Development of Reduction Roadmap	• Third-party Verification of Scope 3	· Strengthening Value Chain Participation
• Direct Reduction Achieved through the Design/Relocation of Zero Energy Building	 Establishment of Renewable Energy Utilization Plan 	· Achieving RE100 and Net Zero

3) Achieving RE100 and Net Zero



4) Indirect Greenhouse Gas Reduction Status (Recent 3-year)

Category	Initiative Project Title	Reduction Amount (tCO2eq)	Performance Period
SK Biopharmaceuticals	RE100 (Green Premium Tariff)	447	2021.07 ~ 2021.12
SK Biopharmaceuticals	RE100 (Green Premium Tariff)	436	2022.03 ~ 2022.12
SK Biopharmaceuticals	RE100 (Green Premium Tariff)	579	2023.01 ~ 2023.12

Classification No.	I -Safety-1	Safety, Health and	Revision Date	Sep. 11,2023
Page	17 / 17	Environment Policy	Revision No.	0.1

7. Risk Management

7.1 Environmental Audit

SK Biopharmaceuticals has obtained environmental management system (ISO 14001) certification for its headquarters and all research laboratories in South Korea. Additionally, the company conducts internal audits annually to verify the status of environmental management system implementation.

In response to the findings from the assessment, we are taking immediate action or establishing improvement plans to address any non-compliance issues. Furthermore, we actively manage our environmental risks by identifying areas for improvement.

Through the annual environmental management review conducted by the SHE department, we assess the status of compliance with environmental management regulations relevant to our business activities and procedures. We also examine the level of response to major environmental trends and regulatory changes.

Additionally, through the environmental management system audits received every three years from the SHE department within the SK Group's SUPEX Pursuit Council, we proactively identify and address environmental compliance issues and risks in advance.